Ocean Biomedical

Ocean Biomedical Earnings Yield

The Earnings Yield of Ocean Biomedical (OCEA) as of Nov 10, 2026 is -1,092.77 %. In the previous year, Earnings Yield was -37,893.24 % — a change of -97.12% (higher).

Earnings Yield

-1,092.77 %

YoY

-97.12%

Last updated:

Earnings Yield of Ocean Biomedical is 2024 -1,092.77 % . Earnings Yield of Ocean Biomedical was 2023 -37,893.24 % . It decreases by -97.12% higher compared to the previous year.

The Ocean Biomedical Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2019
-76.80 USD
Jan 1, 2020
-547.22 USD
Jan 1, 2021
-20,638.58 USD
Jan 1, 2022
187.20 USD
Jan 1, 2023
-37,893.24 USD
Jan 1, 2024
-1,092.77 USD
The Ocean Biomedical Earnings Yield history
YEAREarnings YieldYoY
-1,092.77 %-97.12%
-37,893.24 %-20,342.63%
187.20 %-100.91%
-20,638.58 %+3,671.57%
-547.22 %+612.50%
-76.80 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ocean Biomedical Stock analysis

What does Ocean Biomedical do? Ocean Biomedical, Inc. develops therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company focuses on monoclonal antibodies like Chi3l1-targeting mAbs for non-small cell lung cancer and glioblastoma multiforme. It also offers malaria-related candidates including ODA-570, a vaccine targeting PfSEA-1 and PfGARP, ODA-611, a humanized mAb therapeutic for malaria, and ODA-579, a small molecule malaria therapeutic. These products are developed from research university and medical center assets to accelerate their commercialization. The company monetizes through the development and commercialization of its product candidates. Oncology and malaria-focused therapies represent key segments, with ODA-570, ODA-611, and ODA-579 targeting specific disease areas. Research universities and medical centers are primary collaborators for asset development, providing the foundation for Ocean Biomedical's pipeline. Ocean Biomedical's revenue streams derive from the progression of its therapeutic candidates through development stages. The firm's focus on oncology and malaria therapies drives its product portfolio, with specific candidates like ODA-570, ODA-611, and ODA-579 being central to its commercial strategy. The company accelerates the development of these assets to reach market readiness. Ocean Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ocean Biomedical stock

Earnings Yield of Ocean Biomedical is -1,092.77 % in 2024.

Earnings Yield of Ocean Biomedical changed from -37,893.24 % to -1,092.77 %, representing a -97.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield Ocean Biomedical since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's Ocean Biomedical with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Ocean Biomedical

All Key Metrics — Ocean Biomedical